Humacyte (NASDAQ:HUMA) Director Brady Dougan Sells 549,360 Shares

Humacyte, Inc. (NASDAQ:HUMA) Director Brady Dougan sold 549,360 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $1.83, for a total value of $1,005,328.80. Following the completion of the transaction, the director owned 1,691,685 shares in the company, valued at approximately $3,095,783.55. The trade was a 24.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Humacyte Trading Up 2.2%

HUMA opened at $1.63 on Thursday. Humacyte, Inc. has a one year low of $1.15 and a one year high of $7.48. The company has a market cap of $252.85 million, a P/E ratio of -3.62 and a beta of 1.90. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.93 and a current ratio of 2.45. The business’s 50-day simple moving average is $2.26 and its 200-day simple moving average is $2.40.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09). The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.94 million. As a group, equities research analysts expect that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Benchmark dropped their price objective on Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. HC Wainwright decreased their target price on Humacyte from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, August 12th. TD Cowen decreased their target price on Humacyte from $5.00 to $3.50 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Wall Street Zen cut Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $10.64.

Institutional Trading of Humacyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its stake in Humacyte by 257.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 49,039 shares of the company’s stock valued at $102,000 after acquiring an additional 35,325 shares during the last quarter. Bridgeway Capital Management LLC purchased a new stake in Humacyte during the 2nd quarter valued at approximately $366,000. Clough Capital Partners L P purchased a new stake in Humacyte during the 2nd quarter valued at approximately $504,000. Financial Advisors Network Inc. purchased a new stake in Humacyte during the 2nd quarter valued at approximately $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Humacyte by 25.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,975 shares of the company’s stock valued at $161,000 after acquiring an additional 15,649 shares during the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.